胰激肽原酶联合重组牛碱性成纤维细胞生长因子治疗糖尿病足的临床效果分析

Clinical efficacy of kallidinogenase combined with recombinant bovine basic fibroblast growth factor in treatment of diabetic foot

目的 探究分析胰激肽原酶联合重组牛碱性成纤维细胞生长因子治疗糖尿病足的临床疗效.方法 选取2013年4月至2014年4月在内蒙古牙克石市内蒙古林业总医院内分泌科住院的糖尿病足患者120例,采用随机数字表法分为对照组与观察组,每组60例.对照组给予常规降糖、抗感染、营养神经、局部清创等治疗,观察组在对照组基础上给予胰激肽原酶肌内注射联合重组牛碱性成纤维细胞生长因子喷涂治疗,观察比较2组患者的临床疗效.结果 2组患者的原创面平均大小差异无统计学意义（P＞0.05）.观察组患者皮肤开始生长的平均时间明显早于对照组患者,治疗2周后创面大小明显小于对照组患者,创面愈合时间明显早于对照组患者[（3.7±1.2）d比（11.6±3.5）d,（2.5 ±0.9）cm2比（6.7±2.4） cm2,（22±8）d比（37 ±9）d]（均P＜0.05）.观察组患者的治疗总有效率明显高于对照组[93.3％（56/60）比68.3％ （41/60）] （P ＜0.05）.结论 胰激肽原酶联合重组牛碱性成纤维细胞生长因子治疗糖尿病足临床疗效良好,明显优于常规基础治疗.

Objective To explore the clinical efficacy of kalfidinogenase combined with recombinant bo- vine basic fibroblast growth factor in the treatment of diabetic foot. Methods One hundred and twenty patients with diabetic foot in General Hospital of Inner Mongolia Forestry were enrolled from April 2013 to April 2014 and randomly divided into control group （60 cases） （conventional hypoglyeemie, anti-infection, trophic nerve, local debridement therapy） , and experimental group （60 eases ） [ additionally given kallidinogenase （intramuscular in- jection） combined with recombinant bovine basic fibroblast growth factor（spray） ]. The clinical efficacy was ob- served and compared between the two groups. Results No significant difference was observed regarding the size of original wound surface between the two groups （ P 〉 0.05 ）. The growth start time of skin in experimental group was significantly earlier than that in control group [ （ 3.7 ± 1.2） d vs （ 11.6 ± 3.5 ） d ] ; after 2 weeks of treatment, the wound surface of experimental group was significantly smaller than that of control group [ （ 2.5 ± 0. 9 ）em2 vs （ 6.7 ± 2.4 ） cm2 ] ; the wound healing time in experimental group was significantly earlier than that in control group [（ 22± 8 ） d vs （ 37 ＋ 9 ） d ] （ P 〈 0.05 ）. The total effective rate in experimental group was significantly higher than that in control group[93.3% （56/60） vs 68.3% （41/60） 1 （P 〈0.05）. Conclusion Kallidinogenase combined with recombinant bovine basic fibroblast growth factor is superior to conventional therapy in treatment of diabetic foot.